Breast Cancer Clinical Trials in Austin, Texas

11 studies are recruiting for breast cancer in Austin, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, Austin, Texas

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   New Experimental Therapeutics - NEXT Oncology, Austin, Texas

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

   This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Texas Oncology Central/South, Austin, Texas

   Locations

   231 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT06982521 on ClinicalTrials.gov

4. An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Next Oncology Austin, Austin, Texas

   Locations

   31 in total

   Run by

   BeOne Medicines

   See if you can join NCT07222267 on ClinicalTrials.gov

5. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

   This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of car…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   Texas Oncology - Austin, Austin, Texas

   Locations

   179 in total

   Run by

   Greenwich LifeSciences, Inc.

   See if you can join NCT05232916 on ClinicalTrials.gov

6. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

   The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Texas Oncology - Central South (Balcones Dr), Austin, Texas

   Locations

   202 in total

   Run by

   Pfizer

   See if you can join NCT07062965 on ClinicalTrials.gov

7. Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

   The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may caus…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology Austin, Austin, Texas

   Locations

   5 in total

   Run by

   Conjupro Biotherapeutics, Inc.

   See if you can join NCT07424547 on ClinicalTrials.gov

8. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

   This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

   Stage

   Not phased

   Ages

   40 and older

   Site

   Elligo Health Research, Inc., Austin, Texas

   Locations

   17 in total

   Run by

   Adela, Inc

   See if you can join NCT05366881 on ClinicalTrials.gov

9. Sample Collection for Ongoing Research and Product Evaluation Study

   The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's m…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Natera, Inc., Austin, Texas

   Run by

   Natera, Inc.

   See if you can join NCT07318051 on ClinicalTrials.gov

10. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enabl…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Texas Oncology - Austin, Austin, Texas

    Locations

    134 in total

    Run by

    Agendia

    See if you can join NCT03053193 on ClinicalTrials.gov

11. A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

    This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Texas Oncology PA (Austin), Austin, Texas

    Locations

    13 in total

    Run by

    Processa Pharmaceuticals

    See if you can join NCT06568692 on ClinicalTrials.gov